Shanghai Pharma swallows Cardinal Health’s China unit

The state-owned Chinese company enters new markets while US firm Cardinal Health retreats as new government rules spur consolidation.

Shanghai Pharma swallows Cardinal Health’s China unit

China's Shanghai Pharmaceuticals Holding has agreed to buy the Chinese business of NYSE-listed Cardinal Health for $557 million in cash, potentially making it the largest distributor of imported drugs in the country.

Cardinal Health was the eighth largest drug distributor in China in 2016 across 13 cities and supplying 11,000 medical institutions. The US firm’s sales in China have grown 12.8% year-on-year in 2017 but its earnings slipped 13.2%.

The acquisition...

To continue reading, please login or register for free

Click for more on: acquisitions | china | shanghai pharma | health

Print Edition

FinanceAsia Print Edition

CONFERENCES